Novo Nordisk reported weaker-than-expected net profit for the second quarter, with net profit at just under $3 billion, slightly below forecasts. Earnings before interest and tax also missed expectations. The Danish healthcare company revised its operating profit growth forecast for the rest of the year but raised its sales growth expectations. Shares fell nearly 7%, then recovered slightly. The company's CEO said he expects "attractive growth" in the coming months despite increasing competition and regulatory changes.